Influenza Medication

Global Influenza Medication Market to Reach US$2.0 Billion by 2030

The global market for Influenza Medication estimated at US$1.8 Billion in the year 2024, is expected to reach US$2.0 Billion by 2030, growing at a CAGR of 1.9% over the analysis period 2024-2030. Zanamivir, one of the segments analyzed in the report, is expected to record a 1.2% CAGR and reach US$123.9 Million by the end of the analysis period. Growth in the Oseltamivir segment is estimated at 2.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$483.0 Million While China is Forecast to Grow at 2.7% CAGR

The Influenza Medication market in the U.S. is estimated at US$483.0 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$359.3 Million by the year 2030 trailing a CAGR of 2.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.5% and 1.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.6% CAGR.

Global Influenza Medication Market - Key Trends & Drivers Summarized

Why Is the Demand for Influenza Medication Rising?

The influenza medication market is witnessing a surge in demand due to the recurrent nature of influenza and its significant health impact globally. Seasonal flu outbreaks, alongside pandemic potential strains, create a continuous need for effective antiviral treatments. Influenza medications, such as neuraminidase inhibitors and antiviral drugs, play a crucial role in reducing symptoms and shortening illness duration, thus lowering the strain on healthcare systems during peak flu seasons. With influenza remaining a major public health challenge, particularly among vulnerable populations such as the elderly and immunocompromised, the demand for both prescription and over-the-counter flu medications remains high.

How Are New Therapeutic Approaches Influencing the Market?

Pharmaceutical advancements are leading to the development of new antiviral drugs and therapies that are more effective against evolving influenza strains. The introduction of antiviral treatments with broader spectrums, such as baloxavir marboxil, has expanded options for early and efficient influenza treatment. Furthermore, research into combination therapies is showing promise in combating drug-resistant strains and improving treatment outcomes. Innovations in drug delivery, such as inhalable antivirals and fast-dissolving tablets, are also enhancing patient adherence and providing easier access to treatment. These advances are contributing to a more diverse and responsive influenza medication market.

What Role Do Preventive Strategies Play in Influenza Medication Demand?

Preventive strategies, including vaccination and public health campaigns, play a pivotal role in managing influenza spread but do not eliminate the need for antiviral medications. Seasonal vaccines may not fully cover all strains due to mutation rates, leaving a gap in immunity that medications can address. Additionally, antiviral medications are recommended for high-risk groups and individuals with severe symptoms even with vaccination. Consequently, demand for influenza medications remains high, as they serve as a critical line of defense in managing outbreaks and providing symptomatic relief, particularly when vaccine efficacy varies or is unavailable.

The Growth in the Influenza Medication Market Is Driven by Several Factors

The growth in the influenza medication market is driven by several factors, including the persistent threat of seasonal flu, development of innovative antiviral drugs, and demand for faster-acting treatments. The rising incidence of flu cases each year ensures continuous demand for effective medications, especially in high-risk populations. The emergence of new antiviral treatments with fewer side effects and more targeted efficacy is appealing to healthcare providers. Additionally, the need for swift and accessible treatments during peak flu seasons and in pandemic situations has prompted increased investment in drug research and development. These factors collectively support the sustained expansion of the influenza medication market.

SCOPE OF STUDY:

The report analyzes the Influenza Medication market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Distribution Channel (Hospitals, Clinics, Pharmacies); Product (Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine, Other Products)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 46 Featured) -

• Biostar Pharmaceuticals
• Daiichi Sankyo Co., Ltd.
• F. Hoffmann-La Roche AG
• GlaxoSmithKline PLC
• Natco Pharma Limited
• Sandoz International GmbH
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.